The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment: A meta-analysis

►The “AA” group at A-204C (CYP7A1) had lower serum total cholesterol (TC) levels than the “AC + CC” group.►The “AA” group at A-204C (CYP7A1) had greater reduction in low-density lipoprotein cholesterol (LDL-C) with statin treatment than the “AC + CC” group.►The “GG” group at G2677 A/T (ABCB1) had less reduction in TC and LDL-C with statin treatment than the “non-GG” group.

BackgroundThe relation between the ABCB1 and CYP7A1 genes and serum lipid levels and lipid-lowering efficacy of statin treatment is inconsistent.ObjectiveThe purpose of this meta-analysis was to explore the associations between the ABCB1 and CYP7A1 genes and serum lipid levels and lipid-lowering efficacy of statin treatment.MethodsMEDLINE, EMBASE, and the Cochrane Library databases were searched systematically for studies of associations between relevant single nucleotide polymorphisms C3435 T (ABCB1), G2677 A/T (ABCB1), and A-204C (CYP7A1) and serum lipid levels or statin treatment. Associations were assessed in pooled data by calculating mean difference with 95% confidence intervals.ResultsSeventeen studies with 4890 patients were included in this meta-analysis. The “AA” group at A-204C (CYP7A1) had lower serum total cholesterol (TC) levels than “AC + CC” group. The “AA” group at A-204C (CYP7A1) had greater reduction in low-density lipoprotein cholesterol (LDL-C) with statin treatment than “AC + CC” group. The “GG” group at G2677 A/T (ABCB1) had less reduction in TC and LDL-C with statin treatment than “non-GG” group.ConclusionsThe A-204C (CYP7A1) polymorphism was associated with the level of TC and the lipid-lowering efficacy of statin treatment in the level of LDL-C. The G2677 A/T (ABCB1) polymorphism was associated with the lipid-lowering efficacy of statin treatment in the levels of LDL-C and TC.